JEZ-567 is under clinical development by Novartis and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect JEZ-567’s likelihood of approval (LoA) and phase transition for Refractory Acute Myeloid Leukemia took place on 28 Dec 2020, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

In addition, the same event on 28 Dec 2020 increased JEZ-567’s Phase Transition Success Rate (PTSR) for Relapsed Acute Myeloid Leukemia.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their JEZ-567 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

JEZ-567 overview

JEZ-567 (CART-123) is under development for the treatment of refractory or relapsed acute myeloid leukemia. The therapeutic candidate is an engineered T cell with chimeric antigen receptors (CARs) transduced with lentivirus vector. It is adminstered intravenously. CARs are proteins that allow the T cells to recognize a specific protein CD123 (antigen) on tumor cells in case of acute myeloid leukemia.

Novartis overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

Quick View JEZ-567 LOA Data

Report Segments
  • Innovator
Drug Name
  • JEZ-567
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
  • Sponsor Company: Novartis
  • Originator: University of Pennsylvania
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.